KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Accured Expenses (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Change in Accured Expenses data on record, last reported at $14.0 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 641.42% year-over-year to $14.0 million; the TTM value through Dec 2025 reached $6.9 million, down 52.52%, while the annual FY2025 figure was $6.9 million, 52.52% down from the prior year.
  • Change in Accured Expenses reached $14.0 million in Q4 2025 per PCRX's latest filing, up from $7.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $25.4 million in Q2 2023 and bottomed at -$25.1 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is $228850.0, with a median of $613000.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 8630.97% in 2022, then crashed 1735.88% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $22.5 million in 2021, then tumbled by 105.24% to -$1.2 million in 2022, then plummeted by 1735.88% to -$21.6 million in 2023, then soared by 108.72% to $1.9 million in 2024, then soared by 641.42% to $14.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $14.0 million in Q4 2025, $7.5 million in Q3 2025, and -$15.8 million in Q2 2025.